key: cord-0771562-zrtfyz8s authors: Alhalabi, Omar; Subbiah, Vivek title: Managing Cancer Care during the COVID-19 Pandemic and Beyond date: 2020-04-27 journal: Trends Cancer DOI: 10.1016/j.trecan.2020.04.005 sha: f04e5fa4079c51be63363702ae2e60568b5fa363 doc_id: 771562 cord_uid: zrtfyz8s Abstract COVID-19 pandemic has posed insurmountable challenges to health care systems globally. Cancer therapy is complex, and outcomes are centered on timing. Many oncology societies and health ministries have issued guidelines for cancer care to enable oncologists and patients navigate the crisis. Lessons learned should inform care models for future pandemics. J o u r n a l P r e -p r o o f Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in coronavirus disease 2019 has posed insurmountable challenges to health care systems globally. Cancer therapy is complex, regimented, and outcomes are centered on timing. COVID-19 throws a gauntlet to an already strained system i . Given the extrinsic factors (e.g. resource constraints, high morbidity/mortality) of the COVID-19 pandemic and the intrinsic factors (e.g. high-risk population, lower immune system, many at advanced stage) of cancer patients, practitioners face great responsibilities in ensuring timely, appropriate, compassionate and justified cancer care, while protecting themselves from getting infected with COVID-19 [1] . Reported prevalence of cancer among COVID-19 patients (1%) seems higher than its prevalence in the overall population [2] . Early data from two small and heterogeneous populations [3] shows that 39%-54% of cancer patients were reported to have a severe event (admission to intensive care unit -or death) when infected with COVID-19 [2, 4] . Receiving anti-tumor therapy or surgery within 2-4 weeks of developing symptoms [2, 4] predicted worse outcomes. Oncology often requires a complex set of clinic visits, infusion sessions, surgical stays, radiation therapy appointments, hospital admissions, laboratory blood draws, and imaging studies. Furthermore, patients with cancer need caregiver support. Collectively, caring for cancer patients requires a large number of personal contact points, which means many potential opportunities for viral transmission. The challenges imposed by COVID-19 impact every aspect of care starting with diagnosis of cancer; all the way, to end-of-life care for cancer patients, which concerns patients about receiving suboptimal care (figure 1). To enable oncologists to navigate the COVID-19 public health crisis, all major oncology societies eg. American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), American society of hematology (ASH) ii iii iv and health ministries have formed task-forces and issued resources and guidelines [5] . ASCO, ESMO and ASH websites provide a comprehensive set of "frequently asked questions and answers" based on best level evidence available. In many cases, since there is no evidence, guidelines are based on consensus and committee J o u r n a l P r e -p r o o f recommendations. Most of them refer to CDC guidelines which are constantly being updated. Comprehensive cancer centers have also published their own strategies to maintain cancer care during the COVID-19 outbreak. We summarize potential solutions to these challenges incorporating some of the major society guidelines (Figure 1 ). With no specific vaccine or specific anti-viral therapy for COVID-19 available in the clinic, currently the best we can do for patients with cancer is to prevent them from contracting COVID-19. As a community, we should aim to slow down the spread of COVID-19 and "flatten the curve". Slower spread would avoid overwhelming the health system and allow high-risk patients with cancer to receive necessary routine medical services. To achieve this goal, elective imaging, diagnostic biopsies/procedures have to be prioritized for certain patients e.g. symptomatic patients in metastatic setting, and certain histologies in localized disease settings [6] to avoid compromising chances of cure. How do we manage patients with cancer and COVID-19? Currently, there is no evidence to support changing or withholding chemotherapy or immunotherapy in cancer patients. However, since patients with cancer are uniquely vulnerable to the virus due to a weaker immune system, it is reasonable to withhold or postpone therapy until the patient is asymptomatic. Moreover, similarities between treatment related-adverse events and COVID-19 symptoms (e.g. fever, pneumonitis and colitis) are challenging in patients receiving active cancer treatment. Since we do not know if patients on immunotherapy are at a higher risk for pneumonitis or cytokine storm, streamlining COVID-19 testing with shorter turnaround time and using steroid-sparing strategies in managing immune-related adverse events can help mitigate the impact of COVID-19. Other strategies to treat cancer patients during the COVID-19 pandemic include splitting healthcare teams [7] , implementing tele-multidisciplinary tumor boards, minimizing myelosuppressive agents, expanding the use of personal protective J o u r n a l P r e -p r o o f equipment (PPE), limiting visitors, scanning patients thermally, using oral therapy options when applicable, delaying therapy when in an adjuvant or palliative setting, and allowing certain deviations or violations in protocol patients. Splitting healthcare teams is a strategy where staff is geographically segregated into two teams: clinical (each clinic team has its own registration, triage, venipuncture, consultation room, and lavatories) and non-clinical [7] In disease such as acute myeloid leukemia, where intensive chemotherapy is considered emergent, testing all patients for COVID-19 prior to initiation of induction and delaying or de-intensifying treatment for patients who test positive for COVID-19 has been recommended. Healthcare workers taking care of cancer patients must be uninfected with COVID-19, pass screening for COVID-19 (questionnaire and thermal scan) and follow strict personal protective equipment (PPE) guidelines. Several efforts have aimed at addressing the increasing shortage of PPEs including increasing supply, rationing, and reutilization (+/-sterilization). A challenge facing providers is that being asymptomatic does not necessarily mean one is not currently infected with COVID-19 [8] and cannot infect cancer patients. Therefore, viral testing with PCR could allow for periodic staff monitoring ensuring that staff are infection-free. Prioritizing healthcare workers on high-risk units (bone marrow transplant, and acute leukemia) could address the caveat of limited testing availability. Another aspect of testing is serological (i.e. IgG and IgM antibody) testing, which hypothetically detects established immunity [9, 10] J o u r n a l P r e -p r o o f faces several challenges including selection of the right testing antigen, the ability of antibodies to neutralize the virus, and their ability to prevent re-infection. Over 70 test developers claim an effective test. However, to date, the FDA has issued only one Emergency Use Authorization for a qualitative COVID-19 serological testing vi . Using the analogy of hepatitis B vaccination and surface antibody testing, maturation of antibody testing will help the development of an effective vaccine. Cancer patients frequently travel long distances for access to major cancer centers. Location of the patient, cancer center and travel all pose serious risk. They may require quarantine if they are exposed to COVID-19. In addition, patients with cancer are known to have intermittent and prolonged shedding of respiratory viruses [11] . To avoid risk of harm to themselves, they may require a longer period of quarantine than the general population. Stopping travel and working with local oncologists to treat patients at a local hospital could avoid unnecessary exposure to COVID-19. Other potential solutions would be to reschedule surveillance imaging and rely on telemedicine for clinical surveillance (i.e. clinical history). In addition to analyzing cancer patients who are infected with COVID-19, the collateral damage of COVID-19 in cancer patients who were not infected with COVID-19, yet might have received sub-optimal care due to having restaging scans rescheduled, cancelled or postponed is worth analyzing for future reference. Sensitive discussions of end-of-life, progression of disease, advance directives are critical in oncology and as patients with COVID-19 are not allowed to have visitors, it becomes of utmost importance to document advanced care planning for each patient, sometimes aided by the use of telehealth. Now is the time to ensure patients do not receive care they would not want if they become too severely ill to make their own decisions [12] . Use of videoconferencing for bad news, rather than phone allows for better body language interpretation and effective communication. To compensate for the lack of in-person physician-patient encounter, implementing frequent telemedicine visits with very short-term follow-up will likely help avoid miscommunication. Despite the challenges, the COVID-19 experience is poised to alter how patients with cancer are cared for now and in the future. This crisis has opened new doors for a telemedicine initiative in an unprecedented way. The rapid adoption of telehealth visits, virtual check-in services, e-visits, remote care management and remote patient monitoring aid in patient care management for patients not only living in remote locations but also for patients with cancer who are immunosuppressed and have to social distance. Furthermore, COVID-19 in cancer research is advancing at a breakneck speed, and tele-multidisciplinary tumor boards have broadened collaborations across the globe, for challenging cancer cases as well as for research. In addition, analyzing the "real world" outcomes of patients who received modified and/or alternate cancer care schedules (e.g. chemotherapy, surgery, and radiation) will allow us to identify patient cohorts who may benefit from modified treatment protocols. Results of such analysis could be then validated, through prospective studies. Next-generation clinical operations could use all the invaluable lessons learned when switching from "pandemic Journal Pre-proof J o u r n a l P r e -p r o o f mode" to "normal operations" to improve efficiency, flexibility, anticipate risks and enhance resilience. The dynamic healthcare response to COVID-19 highlights the focus on protecting cancer patients and healthcare workers as well as reducing the impact of COVID-19 on the community. Although the current emphasis is on managing COVD19, the focus in the near future centers on the recovery plan and restoration of the balance of cancer care in the era of COVID-19 and beyond ( Figure 1 ). Undoubtedly, data gathered from caring for cancer patients during COVID-19 will help create care models and predictors for high-risk populations during future epidemiological outbreaks or pandemics. J o u r n a l P r e -p r o o f Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Risk of COVID-19 for patients with cancer Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan The official French guidelines to protect patients with cancer against SARS-CoV-2 infection A War on Two Fronts: Cancer Care in the Time of COVID-19 A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore Universal Screening for SARS-CoV-2 in Women Admitted for Delivery Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Convalescent plasma as a potential therapy for COVID-19 Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy The Importance of Addressing Advance Care Planning and Decisions About Do-Not-Resuscitate Orders During Novel Coronavirus Report of the WHO-China Joint Mission on Coronavirus Disease COVID-19 Patient Care Information COVID-19 AND CANCER Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products Coronavirus (COVID-19) Update: Serological Tests